1.2 Provide a summary (up to 500 words) of the information provided under Section

1.1. It is intended that this summary will be published on the Commission's

website at the date of notification. The summary must be drafted so that it

contains no confidential information or business secrets.

Advent, a globally acting private equity investor, intends to acquire sole control in the

meaning of Art. 3 (1) (b) EC Merger Regulation of the "oxo" products and derivatives

business ("Oxo Group") of Celanese Corporation.

The business activities of the undertakings concerned are:

-- Advent: private equity investor

-- Oxo Group: production and sale of key chemical building blocks and

derivatives for diverse applications including coatings, inks,

lubricants and plasticizers, mainly in Europe and in North

America.